Virgil Simons from Radio Kanal Barcelona has interviewed ICREA researcher Roger Gomis about breast cancer. Gomis is one of the co-authors of an article recently published in Lancet Oncology in which they identified a group of patients with early breast cancer who could benefit from a preventive treatment of metastasis.
Various media, including El Mundo, have reported on the presentation of the National Research Award of the Caja Rural de Soria Scientific Foundation to ICREA researcher Salvador Aznar-Benitah. During the ceremony, Aznar-Benitah reminded attendees that, according to his research, palmitic acid has the ability to fuel the metastasis of various kinds of cancer. He also stressed, "A bad diet significantly shortens life expectancy."
A study published in the Lancet Oncology by an international team led by Prof Rob E. Coleman (University of Sheffield) and Prof Roger R. Gomis (IRB Barcelona) identifies the effect of MAF amplification on the outcome of treatment with adjuvant zoledronic acid in early breast cancer.
This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and both reduce disease recurrence and deaths from breast cancer.
Inbiomotion, an IRB Barcelona spin off company and financed by venture investors Ysios Capital and Caixa Capital Risc, will soon start a confirmatory trial.